Prosecution Insights
Last updated: April 19, 2026
Application No. 16/979,209

COMPOSITIONS AND METHODS FOR DETECTING MYCOBACTERIUM TUBERCULOSIS

Final Rejection §112
Filed
Sep 09, 2020
Examiner
CHEONG, CHEOM-GIL
Art Unit
1645
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Johns Hopkins University
OA Round
2 (Final)
65%
Grant Probability
Moderate
3-4
OA Rounds
3y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allow Rate
112 granted / 173 resolved
+4.7% vs TC avg
Strong +55% interview lift
Without
With
+54.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
31 currently pending
Career history
204
Total Applications
across all art units

Statute-Specific Performance

§101
2.8%
-37.2% vs TC avg
§103
24.4%
-15.6% vs TC avg
§102
15.4%
-24.6% vs TC avg
§112
36.4%
-3.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 173 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claim 14 was canceled. Claims 1-13 and 15 are pending. Claims 1-7 stay withdrawn from further consideration. Claims 8-13 and 15 are under consideration. Withdrawn Rejections Objection of drawings is withdrawn. Applicant provided replacement drawings, thereby obviating this objection. Rejection of Claim 10 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention is withdrawn. Applicant amended the claim 10 to recite “the solid support” instead of “the strip”, thereby obviating this rejection/objection. Rejection of Claims 8-13 and 15 under 35 U.S.C. 103 as being unpatentable over Wallis (WO 1998/004918; IDS) in view of Kumar et al (Antimicrobial Agents Chemotherapy, 2017, 61(3), e02234-16; IDS) is withdrawn. Applicant amended the claim 8 to recite new limitation “for differentiating between the presence of Mycobacterium tuberculosis and non-tuberculosis bacteria in a patient sample”, thereby obviating this rejection. NEW - Claim Rejections - 35 USC § 112 (necessitated by amendments) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 9-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 9-10 recite “the detection step”. There is insufficient antecedent basis for this limitation in the claim. Claims 9-10 depends from claim 8 and claim 8 does not recite detection step. Claim 8 recites only three steps of (a) contacting step; (b) washing step; and (c) incubating step, but does not recite any more step. Therefore, it is unclear which step Applicant intends to recite by “the detection step”. Conclusion Claims 9-10 are rejected. Claims 8, 11-13 and 15 are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHEOM-GIL CHEONG whose telephone number is (571)272-6251. The examiner can normally be reached Monday - Friday 9:00 am - 5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vanessa Ford can be reached at 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHEOM-GIL CHEONG/Examiner, Art Unit 1645 /VANESSA L. FORD/Supervisory Patent Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Sep 09, 2020
Application Filed
Oct 02, 2024
Response after Non-Final Action
Mar 26, 2025
Non-Final Rejection — §112
Sep 30, 2025
Response Filed
Dec 03, 2025
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12558408
INTRATUMORALLY INJECTED YEAST VACCINE
2y 5m to grant Granted Feb 24, 2026
Patent 12559536
CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS
2y 5m to grant Granted Feb 24, 2026
Patent 12540192
CD20 BINDING SINGLE DOMAIN ANTIBODIES
2y 5m to grant Granted Feb 03, 2026
Patent 12528877
BINDING MOLECULES TO CD38 AND PD-L1
2y 5m to grant Granted Jan 20, 2026
Patent 12516117
FULLY HUMAN ANTIBODY TARGETING CD19 AND APPLICATION THEREOF
2y 5m to grant Granted Jan 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+54.9%)
3y 3m
Median Time to Grant
Moderate
PTA Risk
Based on 173 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month